The US FDA will consider several factors when considering whether to grant a waiver of the single shared system Risk Evaluation and Mitigation Strategy requirement for a generic drug sponsor, including the impact a separate system could have on generic entry.
Draft guidance issued May 31 also outlines what ANDA sponsors should include in a waiver request, but FDA made clear that it could act alone in granting a waiver. The...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?